StockData
Jupiter Neurosciences, Inc. logo

Jupiter Neurosciences, Inc. (JUNS) company profile

JUNSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$1.52−0.18 (-10.59%)

Close on Nov 17, 2026Market cap $1.17MP/E –Yield –

About Jupiter Neurosciences

Pharmaceutical Preparations, SIC 2834

Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company focused on developing treatments that utilize an enhanced oral resveratrol formulation to address neuroinflammation, central nervous system disorders, and rare diseases. Its proprietary platform product, JOTROL, delivers resveratrol using micellar technology designed to enhance absorption and bioavailability. The company operates through two main business segments: pharmaceutical operations targeting therapeutic indications such as Parkinson's disease, and consumer products consisting of premium nutritional supplements sold under the Nugevia brand name. The initial Nugevia wellness product line comprises three formulations—GLO, MND, and PWR—marketed directly to consumers for cellular health, cognitive support, and mitochondrial performance.

The company maintains its principal executive offices and headquarters in Jupiter, Florida. Its product operations serve consumers in the United States with planned international reach, supported by regional business development agreements across Southeast Asia, including China, Malaysia, and Singapore. Clinical trial supplies are manufactured in Florida, with underlying technology developed alongside a partner based in Germany.

Summary of the business section of Jupiter Neurosciences's latest annual report, written by StockData.

Company profile

Company

Legal name
Jupiter Neurosciences, Inc.
Founded
2016
Headquarters
Jupiter, FL
Address
1001 North Us Hwy 1, Suite 504 33477
Phone
(561) 406-6154
Employees
5, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
ASSURANCE DIMENSIONS, LLC, Coral Springs, Florida

Stock & identifiers

Ticker
JUNS
Exchange
Nasdaq
IPO date
Dec 3, 2024
Shares outstanding
1M, Aug 14, 2026
Public float
$20.20M, Jun 30, 2025
Filer category
<br>Emerging growth company
Stock splits
1-for-75 reverse, Aug 7, 2026
SEC CIK
1679628
CUSIP
48208B302
ISIN
US48208B3024
FIGI
BBG0130XFNK0
Share class FIGI
BBG0130XFPG0
EIN
47-4828381

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Marshall A. HaywardChief Scientific Officer, Director2,995,077
Christer RosenCEO and Chairman, Director11,078,892
Alison D. SilvaPresident and COO, Director112,777
Alexander Gustaf Erik RosenChief Administrative Officer617,411
Saleem ElmasriChief Financial Officer66,239
Andrew Jon CutlerDirector–
Nicholas H. HemmerlyDirector95,550
Julie B. KampfDirector82,875
Holger WeisDirector96,581
Tomas Jan PhilipsonDirector–
Allison W. BradyDirector21,750

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsOtherTotalvs. prior year
Christer Rosén
Chairman of the Board and Chief Executive Officer
$441.00K$210.00K–$20.41K$671.41K+336%
Saleem Elmasri
Chief Financial Officer
$240.00K$72.00K$102.13K–$414.13K+226%
Marshall Hayward
Chief Scientific Officer
$176.40K$50.00K–$16.15K$242.45K+125%
Alexander Rosén
Chief Administration Officer
$252.00K$72.00K–$15.67K$339.67K+228%
Alison Silva
Chief Business Officer and President
$315.00K$45.00K$255.32K$16.78K$632.10K+356%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had a total of five full-time employees, two full-time consultants, three part-time consultants, and our six Scientific Advisory Board members.”

Corporate history

Events identified from SEC filings

DateEventDetails
Aug 28, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 1, 2026Late filingNotification of late filing
Feb 27, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 14, 2025Late filingNotification of late filing
Apr 21, 2025Auditor changeChange in certifying accountant (8-K Item 4.01)
Mar 25, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 4, 2022ListingRegistration of securities on an exchange (Form 8-A)
Dec 5, 2017Name changeName changed from Jupiter Orphan Therapeutics, Inc. to Jupiter Neurosciences, Inc.

See a number that looks wrong?